Phase I/II Study to Evaluate the Safety, Efficacy, and Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Irinotecan (Primary) ; Panitumumab (Primary) ; Telaglenastat (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Calithera Biosciences
- 30 Aug 2024 Status changed from active, no longer recruiting to completed.
- 01 Jul 2023 Results (n=17) from phase 2 part, presented at the 25th World Congress on Gastrointestinal Cancer
- 06 Mar 2023 Status changed from recruiting to active, no longer recruiting.